Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated ...

Roots Analysis has announced the addition of the “Herceptin® (Trastuzumab) Biosimilars ” report to its list of offerings.   The first trastuzumab ...

The Herceptin Biosimilar Market is carefully analyzed in the report with an emphasis on market dynamics, including key issues and challenges, drivers, trends, ...